Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ACP1 | P24666 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864466 | 0.89 | PDE5A (0.77) | PDE5AMEN1KMT2APOLBABCG2 | |
| SCHEMBL4861504 | 0.87 | PDE5A (0.78) | PDE5AMEN1KMT2AMAPK1ACP1 | |
| SCHEMBL4868103 | 0.84 | PDE5A (0.82) | PDE5AMEN1KMT2AMAPK1POLB | |
| SCHEMBL4867641 | 0.83 | PDE5A (0.78) | PDE5AMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4868215 | 0.81 | PDE5A (0.82) | PDE5AMEN1KMT2AMAPK1POLB | |
| SCHEMBL5100868 | 0.81 | PDE5A (0.72) | PDE5AMEN1KMT2AMAPK1ACP1 | |
| SCHEMBL8482469 | 0.80 | HTT (0.68) | KMT2AMAPK1KDM4E | |
| SCHEMBL1085431 | 0.79 | PDE5A (1.00) | PDE5AMEN1KMT2AMAPK1ACP1 | |
| SCHEMBL4867321 | 0.79 | PDE5A (0.69) | PDE5AMEN1KMT2AMAPK1ACP1 | |
| SCHEMBL4863157 | 0.79 | PDE5A (0.69) | PDE5AMEN1KMT2AMAPK1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | PDE5A 204/4885MEN1 3837/4885KMT2A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.